20
Jul
Messenger RNA platforms have moved far beyond their early identity as vaccine technologies. Their expansion into oncology, rare diseases, cardiovascular medicine, and beyond reflects a convergence of scientific validation, manufacturing advantages, regulatory learning, and unmet clinical need. The same properties that enabled rapid pandemic response are now being leveraged to reshape how medicines are designed and delivered.From Proof of Concept to Broad Clinical ConfidenceThe global deployment of mRNA vaccines provided large-scale human evidence that synthetic mRNA can be effective, scalable, and generally well tolerated. Hundreds of millions of doses demonstrated that transient protein expression can drive robust immune responses without…
